OKRA reaches two million predictions for life science industry six months ahead of schedule

OKRA, the Cambridge-based company using artificial intelligence-driven analytics for the life science industry, has now delivered two million validated predictions in 2020.

This means it has beaten its annual target in half the time expected - and has prompted a new ambitious goal of five million predictions by the end of the year.

The company’s AI platform helps the pharmaceutical industry take decisions at all stages of the drug life cycle - clinical, medical, market access and commercial.

Founder Dr Loubna Bouarfa - who won CEO of the Year at the 2019 Cambridge Independent Science and Technology Awards, said: “Not only did we hit our target six months early, we achieved greater than 95 per cent accuracy.

“We are excited that increasingly, top 10 pharma clients are using OKRA’s AI to inform their decision-making. Reaching the two million mark shows real traction and motivates us to continue helping life science professionals regain power.

“OKRA is in a great position to transform healthcare as we know it. Our AI is enabling life sciences to gain control, gain confidence and regain power.

“Our best in class AI models and non rule-based approach, combined with a hybrid explainability engine that delivers reasons behind why outcomes are being achieved, has allowed us to develop learning systems that are the new digital brain for pharma companies.”

OKRA’s FieldFocus and MarketSphere solutions offer sales and marketing teams tools to predict the future, help launch products and allocate resources for the optimum return.

Read more

OKRA Technologies becomes Veeva partner to drive AI into life science decision-making

OKRA founder calls for open data to drive up cancer care

Enter the 2020 Cambridge Independent Science and Technology Awards